Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cipla
Deloitte
Express Scripts
Merck
Julphar
Cerilliant
Cantor Fitzgerald
Queensland Health

Generated: April 23, 2018

DrugPatentWatch Database Preview

NUBAIN Drug Profile

« Back to Dashboard

Which patents cover Nubain, and when can generic versions of Nubain launch?

Nubain is a drug marketed by Par Pharm Inc and is included in one NDA.

The generic ingredient in NUBAIN is nalbuphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nalbuphine hydrochloride profile page.
Drug patent expirations by year for NUBAIN
Medical Subject Heading (MeSH) Categories for NUBAIN
Synonyms for NUBAIN
(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride
(5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride
17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride hydrate
17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride
20594-83-6 (Parent)
23277-43-2
API0003485
C21H27NO4.HCl
C21H32ClNO6
CCG-220118
CHEBI:7455
CHEMBL1201132
D00843
D06ZXH
DTXSID20177844
EINECS 245-549-9
En 2234A
EN-2234A
HMS1568G18
LS-92174
MLS002154202
Morphinan-3,6-alpha,14-triol, 17-(cyclobutylmethyl)-4,5-alpha-epoxy-, hydrochloride
Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-
Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5alpha,6alpha)-
N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride
Nalbufina clorhidrato [Spanish]
Nalbuphine HCL
NALBUPHINE HYDROCHLORIDE
Nalbuphine hydrochloride (USAN)
Nalbuphine hydrochloride [USAN]
NALBUPHINEHYDROCHLORIDE
Nubain (TN)
PHN-131
Prestwick_344
PW-4142
SCHEMBL41123
SMR001233488
UNII-ZU4275277R
V1613
YZLZPSJXMWGIFH-BCXQGASESA-N
ZU4275277R

US Patents and Regulatory Information for NUBAIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc NUBAIN nalbuphine hydrochloride INJECTABLE;INJECTION 018024-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Par Pharm Inc NUBAIN nalbuphine hydrochloride INJECTABLE;INJECTION 018024-002 May 27, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Daiichi Sankyo
Cipla
Julphar
UBS
Teva
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.